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Background: Lymph node involvement is one of the well-demonstrated prognostic factors in ampullary carcinoma.
The aim of this study is to clarify the role of lymph nodes in predicting the survival outcome of ampullary
carcinoma.
Methods: A cohort of consecutive curative pancreaticoduodenectomies for ampullary carcinoma from 1999 to
2014 was retrospectively analyzed. The effect of node-associated variables, including lymph node status, positive
lymph node number, total harvested lymph node (THLN) number, and lymph node ratio (LNR) was examined using
univariate and multivariate analyses for survival outcome prediction.
Results: In 194 evaluable patients, univariate analysis demonstrated that stage, cell differentiation, perineural
invasion, and nodal status were significant conventional prognostic factors. Concerning the node-associated
variables, positive nodal status, positive lymph node number ≥2, THLN number <14, and LNR ≥0.15 were
significantly associated with poorer survival outcomes, with a 5-year survival rate of 20.3, 38.9, 25.4, and 18 %,
respectively. By multivariate analysis, nodal status and THLN number were two independent predictors of survival.
The most favorable 5-year survival rate was 84.4 % in patients with negative nodal involvement and THLN
number ≥14, compared with the poorest 5-year survival rate of 16.1 % in those with positive nodal status and THLN
number <14.
Conclusions: Tumor biology reflected by lymph node status is the most important independent prognostic factor;
nevertheless, surgical radicality based on THLN number also plays a significant role in the survival outcome for patients
with ampullary carcinoma after curative pancreaticoduodenectomy.
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Patients with periampullary carcinomas, consisting of
pancreatic carcinoma, ampullary carcinoma, carcinoma
of distal common bile duct, and duodenal carcinoma,
have poorer prognosis compared with those with other
gastrointestinal malignancies. Resection of periampullary
carcinoma could provide a better survival outcome than
non-operative biliary drainage or bypass operation [1].
For the proximity of anatomy, periampullary carcinomas* Correspondence: sewang0408@gmail.com
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creativecommons.org/publicdomain/zero/1.0/share the same surgical strategy, which was known as
pancreaticoduodenectomy (also called Whipple proced-
ure [2]). Of periampullary carcinomas, the different biol-
ogy of tumor origins could result in to some degree the
difference of prognosis [3–6]. Ampullary carcinoma, one
of the periampullary carcinomas, accounted for 0.2 % of
all the gastrointestinal carcinomas and 6 % of periampul-
lary tumors [7]. Patients with ampullary carcinomas had a
favorable 5-year survival rate of >35 % after resection,
compared with the worst 5-year survival rate of those with
pancreatic carcinomas, around 7–20 % after resection
[3–5, 8–12]. In addition, several clinicopathological
factors, such as tumor size, resection margin, cell dif-
ferentiation, and lymph node metastasis, have beenicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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survival outcome after pancreaticoduodenectomy for
ampullary carcinoma and other periampullary can-
cers [5, 12–14].
Of these clinicopathological prognostic factors, lymph
node involvement was a well-demonstrated prognostic
factor for ampullary carcinoma. However, the American
Joint Committee on Cancer (AJCC) has classified the
nodal status of ampullary carcinoma into only two cat-
egories, with or without regional lymph node metastasis
[15]. Lately, many investigators tried to further define
the importance of several aspects of lymph node involve-
ment in various malignancies. The lymph node ratio
(LNR), which was defined as the positive node number
among the total harvested lymph node (THLN) number,
attracted lots of attention. LNR was demonstrated to be
a better prediction for survival outcome in many types
of gastrointestinal malignancies including esophageal,
gastric, pancreatic, colorectal, and of course ampullary
carcinoma [16–29]. In addition, an increasing THLN
number has also been claimed to result in more accur-
ate staging and favorable survival outcome in many
types of malignancies [25, 30–35]. Moreover, positive
lymph node number, which represented the extension
of a disease, was another established prognostic factor
in various malignancies arising from the head and neck,
breast, stomach, and colon and rectum, and it was well-
categorized in these carcinomas with tumor-node-
metastasis (TMN) staging system, but not for ampulla
of Vater [15]. Regarding ampullary carcinoma, several
authors had suggested the prognostic importance of
positive lymph node number recently [36–39]. How-
ever, the significance of these node-associated variables
on survival outcome is still not firmly established.
In light of these considerations, the aim of this study
was to clarify the role of these node-associated factors in
predicting the prognosis of ampullary cancer after cura-
tive resection.Methods
The data for patients with periampullary carcinomas who
underwent pancreaticoduodenectomy between October
1999 and September 2014 were retrieved from a prospect-
ively collected database for pancreatic surgery. Only pa-
tients with pathologic diagnosis of ampullary carcinoma,
which was defined as malignancies arising from the ana-
tomical structure of ampulla of Vater, were enrolled. Pa-
tients with the other periampullary malignancies, such as
pancreatic carcinoma, carcinoma of duodenum, carcin-
oma of distal common bile duct, neuroendocrine neo-
plasm, intraductal papillary mucinous neoplasms,
mucinous cystadenocarcinoma, acinar cell carcinoma,
and solid pseudopapillary neoplasms, were excluded.Demographic characteristics and pathologic data were
collected and analyzed.
All patients underwent a standard resection without
extensive retroperitoneal lymph node dissection and
pancreaticojejunostomy or pancreaticogastrostomy re-
construction. The territory of lymph node dissection
consisted of resection of lymph nodes within the con-
fined of the hepatoduodenal ligament, common hepatic
artery, right side of the superior mesenteric artery, and
inferior vena cava. Specimens were examined patho-
logically to determine the tumor size, cell differentiation,
perineural invasion, lymphovascular invasion, residual
tumor status, and lymph node status. Patients with in-
complete lymph node record, undetermined cell differ-
entiation, and diagnosis of carcinoma in situ were
excluded from the analysis. Patients with in-hospital
mortality were excluded as well since these patients
might have the opportunity for better survival outcome
after passing through the surgical events. Surgical resec-
tion with positive surgical margin, which was defined as
the evidence of residual tumor at pancreatic neck and
distal common bile duct cut-end, retroperitoneal margin,
and superior mesenteric and portal vein grooves micro-
scopically or grossly, was assumed as palliative resection.
Patients with palliative resection were also excluded
since there was a significant survival difference between
the curative and palliative groups for periampullary car-
cinomas [40].
All continuous variables were presented as median
(range) or as mean ± standard deviation (SD). When
comparing the two groups, the continuous data were
compared using Student’s t or Wilcoxon rank-sum test
and the categorical variables were compared using chi-
squared or Fisher’s exact test. We identified cutoff
values of three node-associated variables by integrating
the literature review with dividing the entire study
population around the 75th percentiles. Actuarial sur-
vival was estimated using the Kaplan-Meier method,
and univariate differences between the two subgroups
were determined with a log-rank test. All the significant
factors associated with lymph node in univariate ana-
lysis were added up into multivariate analysis subse-
quently. Cox proportional hazard ratio model was used
in multivariate analysis to identify independent predic-
tors of survival outcome. Hazard ratio (HR) and 95 %
confidence intervals (CI) were calculated and reported.
Statistics Version 21 (SPSS, Inc., Chicago, IL, USA) was
used for all statistical analyses, and a P value of <0.05
was considered to indicate statistical significance.Results
During the study period, a total of 718 patients with peri-
ampullary cancers underwent pancreaticoduodenectomy
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confirmed with ampullary carcinoma. Exclusion criteria,
as mentioned in the Methods section, were shown in-
hospital mortality in 13 patients, palliative resection with
positive margin in 7 patients, incomplete lymph node data
in 2 patients, undetermined tumor differentiation in 1 pa-
tient, and carcinoma in situ in 1 patient (Fig. 1). Therefore,
a total of 194 patients with ampullary carcinoma undergo-
ing curative pancreaticoduodenectomy were included in
the analysis.
There were 120 (61.9 %) men and 74 (38.1 %) women
with a median age of 69 years (range 40–90), and the
median tumor size was 2 cm (range 0.7–9.0 cm;
42.3 % ≥2 cm). Sixty-four patients (33 %) were stage I
ampullary carcinoma, 110 patients (56.8 %) were stage
II, and 20 patients (10.3 %) were stage III. On patho-
logic analysis, the majority of the tumors were
moderate-differentiated (n = 137; 73.2 %), negative
perineural invasion (n = 147; 75.8 %), and negative
lymphovascular invasion (n = 153; 78.9 %). Seventy-
two patients (37.1 %) had positive nodal disease,
whereas 122 patients (62.9 %) had no nodal involve-
ment. The 5-year survival rate of the entire cohort
was 42.7 % with a median survival of 45.1 months
and a mean of 83.2 ± 6.2 months. Of the conventional
clinicopathological factors, univariate analysis demon-
strated that stage, tumor differentiation, perineural inva-
sion, and nodal status could significantly predict the
prognosis for patients with ampullary carcinoma after
curative resection. However, age, gender, tumor size, andFig. 1 Inclusion and exclusion criteria for patients with ampullary carcinomlymphovascular invasion had no association with survival
outcome (Table 1).
Table 2 demonstrated the roles of node-associated
factors in predicting survival outcome for patients with
ampullary carcinoma undergoing curative pancreatico-
duodenectomy. The univariate analysis revealed that
nodal status, positive lymph node number, THLN num-
ber, and LNR were all significantly associated with sur-
vival outcome. These significant node-associated variables
were enrolled subsequently in multivariate Cox propor-
tional hazard regression analysis, which revealed that nodal
status and THLN number were independent prognostic
factors, whereas positive lymph node number and LNR
failed to do so. Patients with positive nodal status had
an increased risk of death (HR = 2.12, 95 % CI, 1.05–
4.24; P = 0.036) compared with those with negative
nodal status. Patients with THLN number ≥14 had
improved survival outcome (HR = 0.49, 95 % CI,
0.26–0.93; P = 0.028) in contrast with patients with
THLN number <14.
Clinicopathological characteristics of the cohort cate-
gorized by lymph node status were listed in Table 3.
There was no statistical difference between patients
with positive lymph node status and negative lymph
node status in terms of age and gender. More patients
with lymph node involvement had higher stage, had a
larger tumor size, and had higher rates of poorly differ-
entiated tumors compared with those without lymph
node involvement. Also, the presence of lymphovascu-
lar invasion and perineural invasion was significantlya resulting in the final study cohort
Table 1 Conventional prognostic factors for patients with ampullary carcinoma undergoing curative pancreaticoduodenectomy
Variables
No. of patients n (%)
Survival
P value5-year (%) Median (months) Mean ± SD (months)
Age (years) 0.250
<60 57 (29.4) 49.0 57.7 88.5 ± 11.0
≥60 137 (70.4) 40.7 41.8 78.9 ± 7.2
Gender 0.121
Male 120 (61.9) 39.3 40.0 76.3 ± 8.1
Female 74 (38.1) 48.2 57.7 93.8 ± 9.7
Stage <0.001
I 64 (33) 60.9 – 124 ± 11.0
IIa 55 (28.4) 47.7 57.7 85.6 ± 10.9
IIb 55 (28.4) 21.0 32.8 52.1 ± 9.4
III 20 (10.3) 21.1 21.0 50.2 ± 13.9
Tumor size (cm) 0.282
<2 112 (57.7) 46.0 54.4 88.3 ± 8.1
≥2 82 (42.3) 37.8 40.0 74.3 ± 9.5
Tumor differentiation 0.005
Well 22 (11.8) 42.3 45.1 76.7 ± 18.5
Moderate 137 (73.2) 47.2 52.0 88.6 ± 7.1
Poorly 28 (15) 25.4 23.0 31.7 ± 5.5
Perineural invasion 0.045
No 147 (75.8) 48.5 54.4 89.8 ± 7.0
Yes 47 (24.2) 20.1 34.1 58.3 ± 11.8
Lymphovascular invasion 0.117
No 153 (78.9) 46.0 46.3 89.3 ± 7.0
Yes 41 (21.1) 25.5 41.8 56.7 ± 10.6
Nodal status <0.001
Negative 122 (62.9) 53.9 79.5 98.5 ± 7.9
Positive 72 (37.1) 20.3 28.5 53.4 ± 8.6
SD standard deviation
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(all P < 0.05).
In the following survival analysis, patients were stratified
into four subgroups based on the independent predictors
of nodal status and THLN number (Fig. 2). Patients with
negative nodal status and THLN number ≥14 had the
most favorable 5-year survival rate of 84.4 %, followed by
those with negative nodal status and THLN number <14
(5-year survival rate 48.3 %) and those with positive nodal
status and THLN number ≥14 (30.8 %). The lowest 5-year
survival rate was found in patients with positive nodal sta-
tus and THLN number <14 (16.1 %). In the node-negative
subgroups, patients with THLN number ≥14 had signifi-
cant improved survival outcome compared with those with
THLN number <14 (P = 0.003). However, in the node-
positive subgroups, the survival rate was not statisticallydifferent though patients with THLN number ≥14 had a
higher 5-year survival rate (P = 0.46). There was no survival
difference between patients with negative nodal status and
THLN number <14 and those with positive nodal status
and THLN number ≥14 (P = 0.204).
Discussion
The prognostic significance of lymph node involvement
in cancers is well-established in tumor-node-metastasis
system of AJCC [15]. Of all the other malignancies ex-
cept ampullary carcinoma, lymph node disease is often
further categorized into several groups based on either
positive lymph node number or location. However, nodal
status of ampullary carcinoma is only classified simply
into only two categories, with or without regional lymph
node metastasis. Recently, many authors claimed that
Table 2 The roles of node-associated factors in predicting overall survival outcome for patients with ampullary carcinoma undergoing
curative pancreaticoduodenectomy
Variables
No. of patients n (%)
Survival Univariate analysis Multivariate analysis
5-year (%) Median (months) Mean ± SD (months) P value Hazard ratio 95 % CI P value
Nodal status <0.001 0.036
Negative 122 (62.9) 53.9 79.5 98.5 ± 7.9 (Ref.) –
Positive 72 (37.1) 20.3 28.5 53.4 ± 8.6 2.12 1.05–4.26
THLN number 0.037 0.028
<14 148 (76.3) 38.9 41.8 73.9 ± 6.9 (Ref.) –
≥14 46 (23.7) 56.9 – 109.9 ± 13.5 0.49 0.26–0.93
Positive LN number 0.004 0.938
<2 150 (77.3) 47.2 54.4 90.3 ± 7.2 (Ref.) –
≥2 44 (22.7) 25.4 25.7 58.3 ± 11.5 1.03 0.50–2.14
LNR <0.001 0.665
<0.15 147 (75.8) 50.3 71.8 94.6 ± 7.3 (Ref.) –
≥0.15 47 (24.2) 18.0 26.2 46.4 ± 8.6 1.20 0.53–2.75
THLN total harvested lymph node, LN lymph node, LNR lymph node ratio, SD standard deviation, CI confidence interval
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node number and LNR, could have the improved effi-
cacy for prognostic prediction in ampullary carcinoma
[6, 24–26, 36–39]. Indeed, the current study demon-
strated that lymph node status and THLN number, rather
than positive lymph node number or LNR, independently
determined survival outcome of patients with ampullary
carcinoma after curative resection. The best survival out-
come was seen in patients with negative nodal status and
THLN ≥14 with a favorable 5-year survival rate of 84.4 %,
which was much better than that of patients in other cat-
egories. The importance of these two factors in ampullary
carcinoma had been shown in studies separately based on
the smaller population [9, 25, 30, 41]. The present study
emerged that both lymph node status and THLN number
were independent prognostic factors of ampullary carcin-
oma from a large single-institute data.
Lymph node involvement might imply that the tumor
behavior changes on its way from confinement in origin
organ toward distant metastasis. This aggressiveness of
dissemination via lymphatic system could result in
poorer survival outcome. This study revealed that 32 pa-
tients (37.1 %) with positive nodal status had poorer sur-
vival outcome with a 5-year survival rate of 20.3 %,
compared with 53.9 % in those with negative nodal dis-
ease. By multivariate analysis, nodal status becomes one
of the independent prognostic factors. In our study co-
hort, patients with positive lymph node status had sig-
nificant higher stage, larger tumor size, higher grade of
cell differentiation, presence of perineural invasion, and
lymphovascular invasion (all P < 0.05, Table 3). All these
findings indicated that tumors in patients with positive
nodal status have the tendency toward poorer prognosis.Therefore, nodal status seems to be a reflection of
tumor biology.
Although positive lymph node number and LNR were
significant prognostic factors by univariate analysis in
this study, these two factors failed to become independ-
ent factors by multivariate analysis. Meanwhile, some
studies held the opposite conclusions [24, 25, 28, 36–39].
Sakata et al. [38] examined 71 patients with ampullary car-
cinoma undergoing pancreaticoduodenectomy with re-
gional lymphadenectomy and 34 patients had lymph node
metastasis. The positive lymph node number was identi-
fied as an independent prognostic factor in multivariate
analysis. The cumulative 5-year survival rate was 63 % for
patients with 1–3 positive node whereas 0 % for those
with ≥4 positive nodes. LNR, another node-associated fac-
tor, has drawn much attention for predicting the survival
outcome in patients with various gastrointestinal malig-
nancies [16, 17, 19–21]. LNR may to some degree com-
pensate or standardize variations in inadequate
surgical lymph node dissection [27]. However, some
studies proved that LNR could become an independ-
ent prognostic factor in pancreatic carcinoma, instead
of ampullary carcinoma [23, 26, 28, 29]. Recently,
Pomianowska et al. compared the three periampullary
carcinomas and demonstrated that LNR may be a
powerful prognostic factor only in pancreatic carcin-
oma. Lymph node status adequately determined the
prognosis in ampullary carcinoma [9].
The THLN number might indicate the quality and
radicality of surgical lymphadenectomy. Evaluation of
limited THLNs could bring a major impact on sur-
vival outcome resulting in underestimation of staging
and prognosis in various malignancies [25, 32, 42].










Mean ± SD 66.7 ± 11.7 67.8 ± 10.8
Gender 0.880
Male 76 (62.3 %) 44 (61.1 %)
Female 46 (37.7 %) 28 (38.9 %)
Stage <0.001
I 64 (52.5 %) 0
IIa 55 (45.1 %) 0
IIb 0 55 (76.4 %)




Mean ± SD 2.2 ± 1.2 2.7 ± 1.5
Tumor differentiation 0.002
Well 20 (17.1 %) 2 (2.9 %)
Moderate 85 (72.6 %) 52 (74.3 %)




No 109 (89.3 %) 44 (61.1 %)
Yes 13 (10.7 %) 28 (38.9 %)
Perineural invasion <0.001
No 104 (85.2 %) 43 (69.7 %)
Yes 18 (14.8 %) 29 (40.3 %)
SD standard deviation
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number examined, the better the resulting postgas-
trectomy survival rate in gastric cancer. A linear
trend for superior survival based on more THLNs
could be confirmed for all four stage subgroups of
gastric cancer. A cut-point analysis yielded the greatest
survival difference at ten THLNs [32]. Le Voyer et al. also
reported that THLN number was a significant variable af-
fecting survival outcome among 3411 colorectal cancer pa-
tients [42]. In ampullary carcinoma, the evidence of
increasing THLN number resulting in better prognostic de-
termination was also observed in AJCC. Using the THLN
number 12 to stage the disease properly was recommended
in the 7th edition of AJCC [15]. Our study demonstrated
that patients with THLN number ≥14 had a better 5-yearsurvival rate of 56.9 % compared with that of 38.9 % in pa-
tients with THLN number <14 (P = 0.037). Furthermore,
THLN number independently affected the survival out-
come. The result is echoed by Falconi et al. in a study of 90
patients with ampullary carcinoma after curative resection,
which suggested that adequate THLN number of 16 had fa-
vorable survival outcome [25]. Adequate lymph node dis-
section based on larger THLN number could offer more
“correct” lymph node count or more “accurate” staging.
Smith et al. proposed the mechanism “stage migration” that
patients with larger THLN number had superior survival
outcome in gastric malignancy [32]. In their study, statistics
of linear regressions revealed a proportional increase in
TNM stage as the THLN number increased. Slidell et al.
also suggested that patients without lymph node involve-
ment who had fewer than 12 THLNs might be understaged
[34]. Therefore, THLN number which could be a function
of surgical radicality or quality plays a significant role in
prognosis and accurate staging for ampullary carcinoma.
The evidence of these node-associated variables on survival
outcome is still not firmly established. Several studies re-
ported the impact of THLN on the outcomes of ampullary
carcinoma based on relative smaller population. To the best
of our knowledge, the current cohort demonstrates the
conclusion based on the largest population.
Since THLN number and nodal status were both in-
dependent prognostic factors of ampullary carcinoma,
as expected, patient with THLN number ≥14 and nega-
tive nodal status had the most favorable survival out-
come in this study. In contrast, patients with THLN
number <14 and positive nodal status had poorest sur-
vival outcome. Our analysis also revealed that patients
with THLN number ≥14 had better survival outcome
compared with those with THLN number <14 among
node-positive subgroups (5-year survival rate 30.8 vs.
16.1 %). Furthermore, there was no significant survival
difference between patients with THLN number <14 and
negative nodal status and those with THLN number ≥14
and positive nodal status. These findings indicate that ad-
equate lymph node dissection of THLN number ≥14
might compensate the survival difference caused by ad-
verse tumor biology in patients with lymph node involve-
ment. In addition, the result that patients with THLN
number <14 had poorer survival rate than those with
THLN number ≥14 among node-negative subgroups
might imply that inadequate lymph node dissection might
compromise the survival outcome with favorable tumor
biology. These findings could also provide further evi-
dences to support that these two factors, nodal status and
THLN number, affect the prognosis independently.
Conclusions
Lymph node status which could indicate tumor biology
is the most powerful independent prognostic factor for
Fig. 2 Comparison of survivals for patients with ampullary carcinoma after curative pancreaticoduodenectomy based on nodal status and total
harvested lymph node number
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resection. Nevertheless, THLN number is also an inde-
pendent prognostic factor. Patients with better tumor
biology of negative nodal status and adequate surgical
radicality of THLN number ≥14 have the most favorable
survival outcome. The effort of lymph node dissection
based on THLN number could compensate or com-
promise the prognostic difference caused by tumor biol-
ogy. However, either surgical radicality or stage
migration might be the possible reason to explain why
THLN number impacts on survival outcome, which
needs to be clarified by further studies.Abbreviations
AJCC: American Joint Committee on Cancer; CI: confidence interval;
HR: hazard ratio; LNR: lymph node ratio; SD: standard deviation; THLN: total
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